News

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society discussed the steps needed to take to improve relatively new wellness strategies. [WATCH TIME: 3 minutes]

Investigators noted that while epilepsy did not increase the risk for sleep disorders, there was a strong association identified with TSC-association neuropsychiatric disorders, necessitating early detection.

After changes were made to the AVATAR phase 3 study in Rett syndrome, Anavex provided context on the timing of the adjustments, which were approved by regulatory bodies in the UK and Australia, where the trial was conducted.

Neurology News Network for the week ending February 5, 2022. [WATCH TIME: 4 minutes]

Matthew Klein, MD, MS, FACS, the COO of PTC Therapeutics, discussed a supplemental new drug application for the treatment in a younger group of patients, which has been granted priority review by the FDA.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 4, 2022.

The biotech company announced a collaboration with NS Pharma around CAP-1002’s commercialization and distribution ahead of its HOPE-3 phase 3 trial in Duchenne muscular dystrophy.

In the RAISE trial, patients treated with zilucoplan exhibited clinically meaningful and statistically significant improvement from baseline in Myasthenia Gravis-Activities of Daily Living Profile total score at week 12, when compared with those who received placebo.

The assistant clinical professor at Vanderbilt University School of Medicine discussed ways of incorporating and encouraging women physicians to enter the neurology specialty. [WATCH TIME: 4 minutes]

Although research illustrates the persistence of inequities between women and men in neurology, 3 women leaders shared encouraging thoughts and experiences highlighting the progress made in recent years.

Collaboration can result in greater success than what one can achieve alone, and for women physicians, this rings truer than ever before, writes Jill M. Farmer, DO, MPH.

In light of National Women Physicians Day, the assistant clinical professor at Vanderbilt University School of Medicine commented on the roles women have played historically, and her perspective on where they stand now. [WATCH TIME: 12 minutes]

Theresa Sevilis, DO, writes on picking a career path in medicine as a woman, and how deciding to jump ship from a traditional path was among the best decisions she's made.

The assistant clinical professor at Vanderbilt University School of Medicine shared what National Women Physicians Day means to her, and the history behind its celebration. [WATCH TIME: 6 minutes]

For women, the decision to opt for an unconventional career path can be inspired by conflicting responsibilities and balancing life with work. But, as Sana Syed, MD, MPH, explains, following your passion is still an achievable dream despite these challenges.

Although findings suggest better efficacy of consyntropin when compared with vigabatrin, the randomized trial was underpowered due to incomplete enrollment.

Treatment with blarcamesine resulted in statistically significant improvements on the new primary end point and significantly reduced Rett syndrome symptoms through changes in potential biomarkers of disease pathology.

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society discussed the importance and flexibility of wellness approaches for patients with MS during the pandemic. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Episode 18 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA; and John Greenfield, MD, PhD, of University of Connecticut School of Medicine. [WATCH TIME: 7 minutes]

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society provided insight on the variability in wellness recommendations to treat symptoms of multiple sclerosis. [WATCH TIME: 6 minutes]

The cognitive neurologist at the University of California, San Francisco provided insight on the research needed to explain more about COVID-19’s pathogenesis and the realistic possibility of developing neurocognitive disorders.

A greater proportion of patients treated with 0.25 mg/kg of tenecteplase were free from disability or achieved functional independence compared with those treated with 0.40 mg/kg doses, or alteplase.

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on ongoing developments from the organization, particularly the diagnostics accelerator, which aims at identifying a better way to diagnose Alzheimer disease. [WATCH TIME: 6 minutes]

Expert clinicians offer their insight on conducting trials in pediatric migraine, the pipeline of Alzheimer therapies, disorders of consciousness and COVID-19, and more.

The cognitive neurologist at the University of California, San Francisco discussed a specific analysis that evaluated differences in cerebrospinal fluid in patients who develop cognitive changes following COVID-19 infection. [WATCH TIME: 6 minutes]

Regardless of baseline body mass index, patients who had increases or decreases of 5% or more in BMI had faster cognitive decline over a 5-year follow-up period.

After a prior phase 2 failure in CHANGE-MS showed signs of promise for progressive disease, the final patient visit has been completed in a trial of temelimab in relapsing disease, with results expected before the end of March 2022.